Biofrontera Inc. BFRI
We take great care to ensure that the data presented and summarized in this overview for Biofrontera Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BFRI
Top Purchases
Top Sells
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Insider Transactions at BFRI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 18
2024
|
Hermann Luebbert CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
4,771
+23.88%
|
-
|
|
May 18
2023
|
Hermann Luebbert CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
95,420
+31.37%
|
-
|
|
May 18
2023
|
Erica L. Monaco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
76,336
+36.46%
|
-
|
|
Aug 22
2022
|
Hermann Luebbert CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
113,379
+50.0%
|
-
|
|
Jul 01
2022
|
Erica L. Monaco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,689
+50.0%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 4.77K shares |
|---|